Clinical research organization for psychedelics in the UK Clerkenwell Health raised $2,047,710 (£2.1 million). seed fundingbringing the total to $2,437,750 (£2.5 million), all of which will be used to obtain the London startup fully operational.
Investors in the seed round include Lionheart Ventures, Convergence Partners and Extraordinary ventures. The latter was co-founded by Paulo Pioformer MD of Europe Joyance partner and Matt Cooperwho was also a co-founder Capital One Bank, Tandem Bank and was chairman of Octopus Capital Group.
Clerkenwell’s CEO Tom McDonald believes that the UK is “very well positioned to take advantage of its globally competitive framework for clinical trials”, For this reason, the company decided to start its operations in London.
Paolo Pio added that while psychedelics show great promise in the treatment of mental disorders, the field is “complex and highly regulated” and that the long experience of Clerkenwell’s founders in the field makes them “best positioned”. In the United Kingdom and Europe.”
New Contracts
Clerkenwell assists its clients in designing and conducting drug development and psychedelics-assisted therapy trials and facilitates their large-scale research through commercial centers.
According to the Medicines and Healthcare Products Regulatory Agency (MHRA). Approval, Canadian psychedelics biotech company Psyence PSYGF should start with that Phase 2 clinical study at the London Clerkenwell site on the efficacy and safety of psilocybin-assisted psychotherapy compared to individual psychotherapy for the treatment of adjustment disorders due to a terminal cancer diagnosis.
Clerkenwell also works with Pharma mindset MSTF advance a Phase 1 clinical study Rating of the company Second generation psilocybin compound MSP-1014 for the treatment of Major Depressive Disorder (MDD.)
Also MDMA manufacturer Pharmala Biotech has a new agreement with…
